# Phase 3 Atrial Fibrillation trials recruiting: 30 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials in phase 3 for Atrial Fibrillation that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Atrial Fibrillation trials: 30 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/atrial-fibrillation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07893275 | SGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial | The Cleveland Clinic | Phase 3 | Not yet recruiting | Atrial Fibrillation, Postoperative Atrial Fibrillation | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893275) |
| October 21, 2026 | NCT07887022 | Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a Posterior... | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Atrial Fibrillation (AF) | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887022) |
| September 25, 2026 | NCT07840365 | Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion | Texas Cardiac Arrhythmia Research Foundation | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840365) |
| August 21, 2026 | NCT07779746 | Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2) | Unity Health Toronto | Phase 3 | Not yet recruiting | Atrial Fibrillation, Atrial Flutter, End Stage Kidney Disease (ESRD), Dialysis Patients | 848 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779746) |
| July 31, 2026 | NCT07739888 | Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for... | Novartis Pharmaceuticals | Phase 3 | Not yet recruiting | Atrial Fibrillation (AF) | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739888) |
| June 4, 2026 | NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 15,364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626411) |
| February 25, 2026 | NCT07434661 | Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR | Meshalkin Research Institute of Pathology of Circulation | Phase 3 | Not yet recruiting | Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery, Aortic Valve Surgery, Mitral Valve... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434661) |
| February 24, 2026 | NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 2,628 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430956) |
| November 20, 2025 | NCT07238452 | Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure | University of British Columbia | Phase 3 | Not yet recruiting | Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF) | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238452) |
| September 23, 2025 | NCT07187570 | RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care | Region Stockholm | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187570) |
| December 9, 2024 | NCT06722196 | BiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery | Jilin Heart Hospital | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06722196) |
| December 4, 2024 | NCT06716021 | ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 | Milestone Pharmaceuticals Inc. | Phase 3 | Recruiting | Atrial Fibrillation | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716021) |
| July 15, 2024 | NCT06499857 | Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation | University of Chicago | Phase 3 | Recruiting | Overweight or Obesity, Atrial Fibrillation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06499857) |
| April 22, 2024 | NCT06376916 | Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | Wake Forest University Health Sciences | Phase 3 | Recruiting | Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06376916) |
| September 21, 2023 | NCT06045858 | Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective... | University Hospital, Caen | Phase 3 | Not yet recruiting | Atrial Fibrillation, Peritoneal Dialysis Complication | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045858) |
| July 11, 2023 | NCT05939076 | First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation | Region Örebro County | Phase 3 | Not yet recruiting | Atrial Fibrillation, Persistent | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05939076) |
| July 3, 2023 | NCT05928728 | The COLchicine and Atrial FIBrillation Trial | Herlev and Gentofte Hospital | Phase 3 | Recruiting | Atrial Fibrillation | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05928728) |
| June 6, 2023 | NCT05890664 | Colchicine After Electrocardioversion for Atrial Fibrillation | University Hospital, Basel, Switzerland | Phase 3 | Recruiting | Atrial Fibrillation, Cardiac Arrhythmia | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05890664) |
| May 10, 2023 | NCT05852704 | SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF | Region Örebro County | Phase 3 | Recruiting | Chronic Coronary Syndrome, Atrial Fibrillation | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05852704) |
| May 1, 2023 | NCT05836987 | The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Johns Hopkins University | Phase 3 | Recruiting | Atrial Fibrillation | 5,350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05836987) |
| February 8, 2023 | NCT05717725 | Pulsed-field Ablation Vs. Sham Ablation to Treat AF | Charles University, Czech Republic | Phase 3 | Recruiting | Atrial Fibrillation | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05717725) |
| February 3, 2023 | NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for... | Anthos Therapeutics, Inc. | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712200) |
| January 10, 2023 | NCT05679024 | Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | Region Stockholm | Phase 3 | Recruiting | Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage, Major Bleed, Cardiovascular... | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05679024) |
| September 22, 2022 | NCT05549752 | Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary... | Hippocration General Hospital | Phase 3 | Recruiting | Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05549752) |
| March 24, 2022 | NCT05293080 | Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE | Universitätsklinikum Hamburg-Eppendorf | Phase 3 | Recruiting | Acute Ischemic Stroke, Atrial Fibrillation | 1,746 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05293080) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Region Örebro County | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Region Stockholm | 2 |
| Milestone Pharmaceuticals Inc. | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Jilin Heart Hospital | 1 |
| The Cleveland Clinic | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| University of Oklahoma | 1 |
| Meshalkin Research Institute of Pathology of Circulation | 1 |
| University Hospital, Caen | 1 |
| Universitätsklinikum Hamburg-Eppendorf | 1 |
| University of Chicago | 1 |
| University of Calgary | 1 |
| Hippocration General Hospital | 1 |
| Wake Forest University Health Sciences | 1 |
| Unity Health Toronto | 1 |
| University of British Columbia | 1 |
| Charles University, Czech Republic | 1 |
| Texas Cardiac Arrhythmia Research Foundation | 1 |
| Johns Hopkins University | 1 |
| University Hospital, Lille | 1 |
| Herlev and Gentofte Hospital | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Anthos Therapeutics, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| Canada | 5 |
| Sweden | 5 |
| Germany | 3 |
| United Kingdom | 3 |
| Czechia | 3 |
| France | 2 |
| Brazil | 2 |
| Denmark | 2 |
| China | 2 |
| Hungary | 2 |
| Slovakia | 2 |
| Greece | 2 |
| Japan | 2 |
| Finland | 2 |
| Netherlands | 1 |
| Russia | 1 |
| Switzerland | 1 |
| Argentina | 1 |
| Bulgaria | 1 |
| Chile | 1 |
| Colombia | 1 |
| Croatia | 1 |
| Estonia | 1 |
| India | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Car manufacturers in the United States](https://specstream.ai/data/businesses/car-manufacturers/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
